Characterization and prognostic implication of pulmonary hypertension among patients with myeloproliferative neoplasms

Characterization and prognostic implication of pulmonary hypertension among patients with myeloproliferative neoplasms

Pulmonary hypertension (PH) is a frequent complication of Philadelphia-negative myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). However, its prognostic significance is understudied, thus we aimed to evaluate the effect of...

Full description

Saved in:

Bibliographic Details
Main Authors:	Orly Leiva, Steven Soo, Olivia Liu, Nathaniel R. Smilowitz, Harmony Reynolds, Binita Shah, Samuel Bernard, Joan How, Michelle Hyunju Lee, Gabriela Hobbs
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2025-05-01
Series:	Haematologica
Online Access:	https://haematologica.org/article/view/12061
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Unraveling the impact of lysosomal dysfunction on myeloproliferative neoplasm
by: Hyundong Yoon, et al.
Published: (2024-09-01)

DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications
by: Paola Barone, et al.
Published: (2025-03-01)

Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art
by: Sylvie Hermouet, et al.
Published: (2015-01-01)

Promising Findings in Myeloproliferative Neoplasms and AL Amyloidosis
by: Axel Rüfer
Published: (2022-10-01)

Defining the Thrombotic Risk in Patients with Myeloproliferative Neoplasms
by: Fabrizio Vianello, et al.
Published: (2011-01-01)

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
by: Holly L. Geyer, et al.
Published: (2015-01-01)

Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms
by: Gregor Hoermann, et al.
Published: (2015-01-01)

CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH
by: Paola Guglielmelli, et al.
Published: (2010-05-01)

Prevention, diagnosis and management of myeloproliferative neoplasms: an introduction to a review series
by: Yin Yuan, et al.
Published: (2025-03-01)

Characteristics of regional epidemiological indicators of chronic myeloproliferative neoplasms
by: O. Yu. Vinogradova, et al.
Published: (2025-05-01)

LANDSCAPE OF SOMATIC MUTATIONS OF MYELOPROLIFERATIVE NEOPLASMS IN PAKISTANI PATIENTS
by: Mehreen Ali Khan
Published: (2025-07-01)

Pathogenesis and management of high molecular risk myeloproliferative neoplasms
by: Victoria Y. Ling, et al.
Published: (2024-12-01)

HMGB1 as a biomarker for myeloproliferative neoplasm complicated with atherosclerosis
by: Lunbi Wu, et al.
Published: (2025-05-01)

Precision Medicine in BCR-ABL1 Negative Myeloproliferative Neoplasms
by: Linet Njue, et al.
Published: (2020-12-01)

Elevated Vitamin B12 Levels in Myeloproliferative Neoplasm (MPN) Patients: A Potential Diagnostic and Prognostic Marker
by: Fadul A, et al.
Published: (2024-12-01)

Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan
by: Yoko Edahiro, et al.
Published: (2024-12-01)

TREATMENT OF BLAST PHASE MYELOPROLIFERATIVE NEOPLASM WITH THE COMBINATION OF AZACITIDINE, VENETOCLAX AND RUXOLITINIB
by: Fidan Khalilova, et al.
Published: (2025-07-01)

Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms
by: Joshua W. Bliss, et al.
Published: (2024-12-01)

Not just for mature audiences: myeloproliferative neoplasms in children, adolescents, and young adults
by: Linda Resar, et al.
Published: (2025-05-01)

JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms
by: Mar Bellido, et al.
Published: (2012-01-01)

RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia
by: Tim Kong, et al.
Published: (2025-01-01)

Association of Pruritus With Comorbidities and Survival in Myeloproliferative Neoplasms: A Systematic Review of the Literature
by: J. Saucereau, et al.
Published: (2025-06-01)

Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms
by: Dandan Yu, et al.
Published: (2025-06-01)

JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms
by: Nabih Maslah, et al.
Published: (2025-07-01)

HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative Neoplasms
by: Margaux Sevin, et al.
Published: (2015-01-01)

Application of heteroduplex analysis for CALR mutation screening detection in patients with Ph-myeloproliferative neoplasms
by: T. N. Subbotina, et al.
Published: (2021-06-01)

A Case of Myeloproliferative Neoplasm with Eosinophilia Associated with PCM1-JAK2 Rearrangement
by: Wen Zhou, et al.
Published: (2025-01-01)

MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria
by: Mohamed A. Yassin, et al.
Published: (2020-07-01)

PO09 | Comparison of different aggregometry methods for evaluation of platelet function in patients with myeloproliferative neoplasms
Published: (2025-08-01)

Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms
by: Xiaodong Guo, et al.
Published: (2025-08-01)

A Dual-Feature Framework for Enhanced Diagnosis of Myeloproliferative Neoplasm Subtypes Using Artificial Intelligence
by: Amna Bamaqa, et al.
Published: (2025-06-01)

Granulocytic Expression of CD11b/CD18 and Thrombotic Risk in Patients with Myeloproliferative Neoplasms
by: Doroteya Todorieva-Todorova, et al.
Published: (2021-06-01)

Prevalence and clinical significance of sarcopenia in patients with chronic myeloproliferative neoplasms: epidemiology, diagnosis, and intervention strategies
by: Adelina G. Garifullina, et al.
Published: (2025-01-01)

USP5 inhibition via bone marrow-targeted engineered exosomes for myeloproliferative neoplasms therapy
by: Wenjun Wang, et al.
Published: (2025-07-01)

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling
by: Sivahari Prasad Gorantla, et al.
Published: (2025-05-01)

Pathways to myeloproliferative neoplasm presentation and time to diagnosis: results from a cross-sectional study
by: Emma-Louise Tarburn, et al.
Published: (2025-04-01)

Ph-negative chronic myeloproliferative neoplasm (primary myelofibrosis)– as one of the reasons of the Budd-Chiari syndrome.
by: Maria Dmitrievna Sanatko
Published: (2012-06-01)

Case Report of Hepatic Sinusoidal Obstruction Syndrome Complicated with Myeloproliferative Neoplasm and Focal Segmental Glomerulosclerosis
by: Yuxuan Song, et al.
Published: (2025-07-01)

Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms
by: Leah A. Goldberg, et al.
Published: (2025-05-01)

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
by: M B Agarwal, et al.
Published: (2015-01-01)